help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millard, W. J.
Right arrow Articles by Martin, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Millard, W. J.
Right arrow Articles by Martin, J. B.

Endocrinology, Vol 110, 540-550, Copyright © 1982 by Endocrine Society

ARTICLES

Evidence that reduced growth hormone secretion observed in monosodium glutamate-treated rats is the result of a deficiency in growth hormone- releasing factor

WJ Millard, JB Martin Jr, J Audet, SM Sagar and JB Martin

The present experiments were designed to examine various aspects of GH secretion in adult male rats given monosodium glutamate (MSG; 4 mg/g BW, sc) during the neonatal period. MSG-treated animals sustained lesions localized to the hypothalamic arcuate nuclei (ARC) and had reduced nasal-anal lengths and body weights. Anterior pituitary (AP) weights were decreased, but AP concentrations of GH and PRL were not significantly altered. Analysis of pulsatile GH secretion showed depressed GH pulses and prolonged GH trough periods. Mean 5-h plasma GH levels were reduced, whereas PRL levels were not affected. Morphine sulfate (MS) at doses of 0.01, 0.1, 1.0, and 3.0 mg/kg induced a prompt rise in GH during the 45 min after drug administration in controls. MSG- treated animals showed a significant rise in GH only with 1.0 and 3.0 mg/kg MS. A significant elevation in PRL was found in both control and MSG-treated animals after 1.0 and 3.0 mg/kg MS. The pentobarbital- induced rise in GH was also blunted in MSG-treated animals. MSG-treated animals which were administered antisomatostatin serum showed elevated GH trough and mean GH levels, with no apparent effect on GH peak levels. In view of the mechanisms by which MS and pentobarbital act to increase GH secretion, the present data suggest that the GH regulatory deficit observed in MSG-treated rats is due to a relative loss of GH- releasing factor secondary to ARC damage.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
A. Kaufhold, P. K. Nigam, R. N. Dhir, and B. H. Shapiro
Prevention of Latently Expressed CYP2C11, CYP3A2, and Growth Hormone Defects in Neonatally Monosodium Glutamate-Treated Male Rats by the N-Methyl-D-Aspartate Receptor Antagonist Dizocilpine Maleate
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 490 - 496.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Kawai, S. M. Bandiera, T. K. H. Chang, F. M. Poulet, P. M. Vancutsem, and G. D. Bellward
Modulation of Hepatic CYP2A1, CYP2C11, and CYP3A9 Expression in Adult Rats by Neonatal Administration of Tamoxifen
Drug Metab. Dispos., December 1, 1999; 27(12): 1392 - 1398.
[Abstract] [Full Text]

Home page
 ScienceHome page
G. Tannenbaum
Growth hormone-releasing factor: direct effects on growth hormone, glucose, and behavior via the brain
Science, October 26, 1984; 226(4673): 464 - 466.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society